Jump to the top of the page

Investment Banking

The Quarterly Rx: Q3 2022 U.S. Biopharma Recap

While biopharma markets stabilized in Q3 2022—providing issuers with the most constructive financing environment we have seen year-to-date—macroeconomic issues remain the key headline risk for the near term. Key biopharma indices bounced off multiyear lows, driven by encouraging signs of M&A, meaningful positive clinical news, and broad sector short covering. William Blair's Biopharma team shares perspectives in “The Quarterly Rx: Q3 2022 U.S. Biopharma Recap.

Complete the form below to download your copy of the report.

Delivered to Your Inbox

Stay up-to-date with the latest William Blair news and insights

Subscribe to News Alerts

More News and Insights

  • William Blair Adds Managing Director Focused on Insurance, Financial Services Sectors

    William Blair announced today the expansion of the firm’s financial services team with the addition of William Nay as managing director.

    Read more

  • Yesway, Inc.: Initiation of Research Coverage

    William Blair initiated research coverage of Yesway, Inc. (YSWY $21.40), a U.S.-based convenience store chain that primarily operates across the Great Plains and Southwest under the Yesway and Allsup’s banners and offers fuel, groceries, general merchandise, and prepared foods—most notably its signature fried burrito.

    Read more

  • Perspective Therapeutics, Inc.: Initiation of Research Coverage

    William Blair initiated research coverage of Perspective Therapeutics, Inc., a clinical-stage radiopharmaceuticals company that focuses on the lead-212 payload.

    Read more
See more insights

Are you sure you want to leave?

Information contained on the internet is not subject to William Blair & Company's control or review, and may not be accurate.

For disclosure information, please visit www.williamblair.com/disclosures